secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenetic Biosciences, Inc. (XBIO)
CIK:        0001534525
Form:       8-K
Filed at:   2021-11-12T23:59:59+00:00
Accession:  0001683168-21-005470
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenetic Biosciences reports Q3 net loss of ~$1.4M; cash $19.7M after $12.5M private placement
--------------------------------------------------------------------------------

- Net loss ~$1.4M for Q3 2021; R&D expenses up 36.1% to $0.8M, G&A up 17.5% to $0.9M.
- Ended Q3 with cash ~$19.7M and working capital ~$19.5M after July $12.5M private placement.
- XCART platform progressing toward IND-enabling studies; issued US patent for co-administration with personalized vaccine.
- PolyXen royalty income ~$0.3M from Takeda sublicense in Q3; partner Pharmsynthez filed Epolong registration in Russia.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534525/000168316821005470/0001683168-21-005470-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534525/000168316821005470/xenetic_i8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-21-005470

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer